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ABSTRACT
Sirtuins 1 and 2 (SIRT1/2) are two NAD-dependent
deacetylases with major roles in inflammation. In
addition to deacetylating histones and other pro-
teins, SIRT1/2-mediated regulation is coupled with
other epigenetic enzymes. Here, we investigate the
links between SIRT1/2 activity and DNA methy-
lation in macrophage differentiation due to their
relevance in myeloid cells. SIRT1/2 display dras-
tic upregulation during macrophage differentiation
and their inhibition impacts the expression of many
inflammation-related genes. In this context, SIRT1/2
inhibition abrogates DNA methylation gains, but
does not affect demethylation. Inhibition of hyper-
methylation occurs at many inflammatory loci, which
results in more drastic upregulation of their expres-
sion upon macrophage polarization following bac-
terial lipopolysaccharide (LPS) challenge. SIRT1/2-
mediated gains of methylation concur with de-
creases in activating histone marks, and their inhibi-
tion revert these histone marks to resemble an open
chromatin. Remarkably, specific inhibition of DNA
methyltransferases is sufficient to upregulate inflam-
matory genes that are maintained in a silent state by
SIRT1/2. Both SIRT1 and SIRT2 directly interact with
DNMT3B, and their binding to proinflammatory genes
is lost upon exposure to LPS or through pharmaco-
logical inhibition of their activity. In all, we describe a
novel role for SIRT1/2 to restrict premature activation
of proinflammatory genes.
INTRODUCTION
Macrophages (MACs) are required to respond to a wide
range of environmental stimuli which specify their func-
tions. Historically classified as both pro-inflammatory and
anti-inflammatory, MACs provide versatile and dynamic
responses as part of the innate immune system. In order
to acquire the corresponding phenotypes of each cell type,
MACs undergo very specific changes in gene expression that
are mediated by the complex interplay between signalling,
transcriptional and epigenetic machineries. Deregulation of
these processes results in abnormal MAC function which
ultimately forms the basis for many immune diseases.
Sirtuins, highly conserved proteins that belong to the
family of class III histone deacetylases, are key regulators
of transcriptional and epigenetic landscape. This family of
proteins has been implicated in a wide range of biologi-
cal and pathological processes, including metabolism, ag-
ing and inflammation. One important member of the sir-
tuin family, SIRT1, regulates inflammation in myeloid cells
(1,2). Originally reported to deacetylate histones H3 and
H4, SIRT1 substrates have now been expanded to sev-
eral transcription factors (TFs), including the p65 sub-
unit of NF-B and p53. SIRT1 also determines the epige-
netic landscape through interactions with other chromatin-
modifying enzymes (3–6). SIRT1 is induced in mature
macrophages by anti-inflammatory conditions, such as the
exposure to Th2-cytokines and glucocorticoids (7). In fact,
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SIRT1 has been extensively described to be integral to
macrophage biology through several distinct mechanisms.
For instance, SIRT1 plays a key role in the self-renewal
of murine macrophages through cell cycle and longevity
pathways (8). Also, in a murine model of atherosclerosis,
in vivo treatment with SIRT1-specific inhibitor EX-527 re-
sulted in increased atherosclerotic lesion size through in-
creased intraplaque macrophage infiltration and impaired
autophagy (9). Finally, macrophages isolated from SIRT1
transgenic mice exhibited enhanced polarization toward the
M2 axis, coupled with decreased expression of TNF and
IL-1 (10).
Another member of the sirtuin family, SIRT2, tran-
siently shuttles to the nucleus during G2/M transition and
shares redundant roles with SIRT1 in the deacetylation of
H4K16 and p65 (11,12). Although less described, SIRT2
also plays a role in macrophage biology, as SIRT2 ame-
liorates LPS-induced iNOS expression in bone marrow
macrophages (13) and its activities are required for the
hypo-inflammation phase of sepsis in a mouse model (14).
DNA methylation is another crucial regulator of MAC
differentiation, and many key genes have been identified to
undergo rapid demethylation during terminal myeloid dif-
ferentiation (15,16), whereas others undergo slower gains of
methylation. In addition, key enzymes in maintaining DNA
methylation balance, such as DNA methyltransferase 3A
(DNMT3A) (17) and Ten-Eleven-Translocation 2 (TET2),
are frequently mutated in myeloid leukaemia (18,19), re-
inforcing the importance of DNA methylation in myeloid
differentiation. Furthermore, in specific contexts of ter-
minal differentiation, DNMTs are required to yield the
final functional phenotype, as such that downregulation
of DNMT3A abolishes immune-suppressive properties of
myeloid-derived suppressor cells (20).
In humans, MACs arise from circulating or resident
monocytes (MOs) which are largely present in the blood,
spleen and bone marrow. MAC differentiation can be
achieved in vitro by the addition of M-CSF to isolated pe-
ripheral blood MOs. M-CSF MACs can be further po-
larized into a pro-inflammatory or anti-inflammatory phe-
notype when exposed to lipopolysaccharide (LPS) or IL-
4/IL-10 respectively. The plasticity of these MACs render
them responsive to further polarization depending on the
environmental stimuli encountered, hence they are coined
as M0 MACs. Despite the relevance of sirtuins and DNA
methylation in myeloid differentiation and function, their
interplay has not been explored in this context until now.
In the present study, we observed a rapid upregulation of
SIRT1/2 proteins upon the addition of M-CSF to MOs to
stimulate MAC differentiation, prior to further polariza-
tion. We studied the effects of SIRT1/2 inhibition on global
gene expression, DNA methylation and changes in various
histone marks during macrophage differentiation and ac-
tivation. In brief, we report a novel role for SIRT1/2 in
the sequential and hierarchical deposition of DNA methy-
lation, involving a direct interaction with DNMT3B, and
the inhibition of active histone H3 modifications in pro-
inflammatory genes to prevent their premature activation
during differentiation and prior to the encounter with bac-
terial antigens.
MATERIALS AND METHODS
MO isolation, differentiation and culture
Buffy coats used in the study were obtained from anony-
mous donors via the Catalan Blood and Tissue Bank (Banc
de Sang i Teixits; BST). All donors signed an informed
consent form prior to donation, and all donations were
in accordance with the guidelines of the World Medical
Association (WMA) Declaration of Helsinki. Peripheral
blood mononuclear cells (PBMCs) were extracted by layer-
ing buffy coats on Lymphocytes Isolation Solution (Rafer,
Zaragoza, Spain) and centrifuged at 800 g for 30 min in the
absence of braking. After collection, PBMCs were washed
with phosphate-buffered saline (PBS) and MOs were pu-
rified using CD14 MicroBeads (Miltenyi Biotec, Bergisch
Gladbach, Germany) following the manufacturers’ instruc-
tions. Following cell separation, CD14+ MOs were attached
to plates by incubation with serum-free medium and then
cultured in -minimal essential medium (-MEM; Invit-
rogen, Carlsbad, CA, USA) containing 10% fetal bovine
serum, 1% Penicillin Streptomycin (Gibco Thermo Fisher
Scientific, MA, USA) and supplemented with 25 ng/ml hu-
man M-CSF (PeproTech EC, London, UF) for MAC differ-
entiation. For MAC activation, 10 ng/ml of LPS (from E.
coli O111:B4, Sigma-Aldrich, Darmstadt, Germany) were
added at day 5 of differentiation for 18 hrs. To inhibit
SIRT1, SIRT2 and in combination, 70 M of EX-527
(Sigma-Aldrich, Missouri, USA), 4 M of AGK2 (Sigma-
Aldrich) and 50 M of Cambinol (BioVision, California,
USA) were added, respectively, to MOs at day 0 in the pres-
ence of M-CSF. Cytokines and inhibitors were refreshed ev-
ery two days until the end of the experiment. Corresponding
volumes of DMSO were used as control.
Flow cytometry analysis
Cells were detached mechanically using cell scrapers and
resuspended in staining buffer (PBS containing 2 mM of
EDTA and 4% FBS), followed by incubation with hu-
man FcR Blocking Reagent (Miltenyi Biotec). Cells were
counted and 1 × 105 cells were stained with fluorochrom-
conjugated antibodies against CD163-FITC (BioLegend,
California, USA), CD86-APC (Miltenyi Biotec), CD83-
APC (Miltenyi Biotec) and CD80-PE (Miltenyi Biotec) for
20 min on ice protected from light. Cells were washed
twice with staining buffer and fixed with PBS containing
4% paraformaldehyde (Electron Microscopy Sciences, PA,
USA). 8000 events were acquired using Gallios Flow Cy-
tometer (Beckman Coulter, CA, USA) and analyzed using
the Kaluza software (Backman Coulter).
Quantitative real-time PCR
Total RNA was isolated utilizing Maxwell® RSC sim-
plyRNA Cells Kit (Promega, Wisconsin, USA) and re-
verse transcription was performed using Transcriptor First
Strand cDNA Synthesis Kit (Roche, Basel, Switzerland)
all according to manufacturers’ instructions. LightCycler®
480 SYBR Green I Master mix (Roche) and forward and re-
verse primers (sequences annotated in Supplementary Table
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S1) were added to the cDNA. Quantitative PCR was carried
out using LightCycler® 480 II System (Roche) and results
were analyzed using the corresponding LightCycler® 480
Software (Roche). Relative quantification of target genes
was calculated by the standard double delta Ct method, and
all genes were normalized against the housekeeping gene
ribosomal protein L38 (RPL38). All statistical tests were
performed using Ct values in which statistical significance
was defined as P < 0.05 by paired Student’s t-test.
Western blotting
Protein expression was visualized by western blotting,
in which electrophoresis and transfer were performed as
previously described (16). Membranes were then incubated
with primary antibodies against SIRT1 (07-131, Millipore),
SIRT2 (ab51023, Abcam), NF-B p65 (sc-372, Santa
Cruz Biotechnologies, TX, USA), p65K310ac (ab19840,
Abcam, Cambridge, UK), DNMT1 (NB100-56519,
Novus), DNMT3A (3598, Cell Signaling), DNMT3B
(sc-20704, Santa Cruz) and -Actin (ab6276; Abcam).
HRP-conjugated mouse and rabbit secondary antibodies
were from Thermo Fisher (Massachusetts, USA) and
Abcam respectively. Membranes were developed by Amer-
sham™ ECL™ Western Blotting Detection Reagents (GE
Healthcare, Illinois, USA) and signals were detected by
Amersham™ Imager 600 (GE Healthcare). Band intensities
were quantified using the Fiji Software, and relative protein
expression was calculated by normalizing against -Actin
expression.
Enzyme-linked immunosorbent assay (ELISA)
Released cytokines IL-10 and IL-1 were detected using
ELISA kits provided by BioLegend and Invitrogen (Cali-
fornia, USA), respectively, according to manufacturers’ in-
structions. Absorbance was measured at 450 nm using Pow-
erWave™ XS microplate reader (BioTek® Instruments, Ver-
mont, USA).
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed as previously described (16).
Briefly, MOs, DMSO- and cambinol-treated day 5 and
LPS-stimulated MACs were crosslinked with 1% methanol-
free formaldehyde (Thermo Fisher) for 15 min and sub-
jected to immunoprecipitation after sonication. ChIP ex-
periments were performed using the LowCell# ChIP kit™
protein A (Diagenode, Liège, Belgium). We used antibod-
ies against acetylated lysine 16 of histone H4 (H4K16ac;
07-329, Millipore), monomethylated lysine 4 of histone H3
(H3K4me1; ab8895, Abcam), trimethylated lysine 4 of hi-
stone H3 (H3K4me3; CS200580, Millipore), acetylated ly-
sine 27 of histone H3 (H3K27ac; 07-360 Millipore), SIRT1
(07-131, Millipore), SIRT2 (ab51023, Abcam), PU.1 (PA5-
17505, Invitrogen) and DNMT3B (sc-20704, Santa Cruz).
Corresponding rabbit IgG (Diagenode) is used as con-
trol. Protein binding was analyzed by real-time quantitative
PCR, and data are represented as ratio of the enriched frac-
tion with respect to input. ChIP primers were designed for
the areas flanking differentially methylated CpGs and their
sequences are shown in Supplementary Table S1.
Co-immunoprecipitation (Co-IP) assays
Co-IP assays were performed using M-CSF macrophages
differentiated from CD14+ monocytes for 5 days. Cell ex-
tracts were prepared in lysis buffer [50 mM Tris–HCl, pH
7.5, 1 mM EDTA, 150 mM NaCl, 1% Triton-X-100, pro-
tease inhibitor cocktail (cOmplete™, Merck)] with corre-
sponding units of Benzonase (Sigma) and incubated at 4◦C
for 4 h. 50 l of supernatant was saved as input and diluted
with 2× Laemmli sample buffer (4% SDS, 20% glycerol,
120 mM Tris–HCl, pH 6.8). Supernatant was first incubated
with PureProteome™ Protein A/G Mix Magnetic Beads
(Millipore) for 1 h to remove background signal. Samples
then incubated overnight at 4◦C with corresponding anti-
bodies against DNMT1 (NB100-56519, Novus), DNMT3A
(3598, Cell Signaling), DNMT3B (sc-20704, Santa Cruz),
SIRT1 (07-131, Millipore), and SIRT2 (ab51023, Abcam)
according to the specifications of each antibody. Negative
controls were incubated with rabbit (12-370; Merck Milli-
pore) and mouse (12-371; Merck Millipore) IgGs. Subse-
quently, samples were incubated with magnetic beads at 4◦C
for 2 h, and beads were then washed three times with lysis
buffer. For sample elution, 100 l of 1× Laemmli sample
buffer was added to beads. Samples and inputs were de-
natured at 95◦C in the presence of 1% -mercaptoethanol.
Whole-cell extracts and IP samples were visualized by west-
ern blotting, as described above.
Transfection of primary human MOs
For RNA knockdown experiments, we transfected iso-
lated monocytes with SIRT1 Silencer® pre-designed
siRNA (AM16708-136457, Ambion, TX, USA), and ON-
TARGETplus SMARTpool siRNAs against SIRT2 (L-
004826-00), DNMT3A (L-006672-01) and DNMT3B (L-
006395-00), with non-targeting siRNA as control, all pro-
vided by Dharmacon (Colorado, USA). Transfections were
carried in MAC differentiation media using Lipofectamine
3000 Reagent (Thermo Fisher Scientific Co., Carlsbad, CA,
USA) according to manufacturer’s instructions. Media con-
taining siRNA and Lipofectamine were removed after 6–8
h following transfections, and this was repeated every 48 h
in M-CSF differentiation media for 5 days, in which MACs
were subsequently stimulated with LPS for 18 h. Transfec-
tion efficiencies were examined by western blotting.
Bisulfite modification and pyrosequencing
Total DNA was extracted by the proteinase K protocol.
Briefly, cells were lysed using lysis buffer (50 mM Tris pH
8.8, 10 mM EDTA pH 8.3, 100 mM NaCl, 1% SDS) in
the presence of Proteinase K (Roche), and nucleic acids
and lipids were separated by repeated centrifugation. DNA
was precipitated using isopropanol and washed with 75%
ethanol. 300 g of isolated DNA were bisulfite (BS)-
converted using EZ DNA Methylation-Gold™ Kit (Zymo
Research, CA, USA) according to manufacturers’ instruc-
tions. BS-converted DNA (∼20 ng) was used as template
for further pyrosequencing. Primers for PCR amplification
and sequencing were designed using the PyroMark® As-
say Design Software 2.0 (QIAGEN, Hilden, Germany) and
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sequences are listed in Supplementary Table S1. Conven-
tional PCR was carried out using IMMOLASE™ DNA
Polymerase kit (Bioline, London, UK) and PCR products
were pyrosequenced with PyroMark® Q24 System (QIA-
GEN).
Gene expression array and analysis
The quality of extracted total RNA was first analyzed by the
2100 Bioanalyzer System (Agilent, CA, USA), and 100 ng
of excellent quality RNA (RNA Integrity number of > 9)
was then hybridized on Human Clariom S™ Assay arrays
(Thermo Fisher) carried out at/by the High Technology
Unit (UAT), at Vall d’Hebron Research Institute (VHIR)
following manufacturers’ instructions. Downstream data
normalization and analysis were performed using statisti-
cal analysis language R in combination with Bioconductor
(https://www.bioconductor.org) and CRAN (https://cran.r-
project.org) repository packages. Firstly, background cor-
rection was performed using Robust Microarray Analy-
sis (RMA) normalization provided by oligo package. Each
probe was then annotated using clariomshumantranscript-
cluster.db package, and the average expression level was cal-
culated if more than one probe was mapped to the same
gene. Downstream statistical analyses were performed using
an eBayes-moderated paired t-test provided by limma pack-
age to obtain log2 fold change (log2FC), P-value and ad-
justed P-value (Benjamini Hochberg-calculated FDR) be-
tween sample groups. Genes that displayed statistically sig-
nificant tests (P-value < 0.01 and FDR < 0.05) were con-
sidered differentially expressed. Heatmaps were generated
using calculated z-scores.
DNA methylation profiling and analysis
500 ng of BS-converted DNA were hybridized on In-
finium MethylationEPIC BeadChip array (Illumina, Inc.,
San Diego, CA, USA) following manufacturers’ instruc-
tions. This array covers over 850 000 (850K) CpG methy-
lation sites per sample at single-nucleotide resolution, cov-
ering 99% of RefSeq genes. Probe fluorescence was detected
by BeadArray Reader (Illumina, Inc.), and image process-
ing and intensity data extraction were performed as previ-
ously described (16). For downstream normalization, filter-
ing and analysis, standard pipelines from minfi and limma
packages were used and data was processed using statis-
tical analysis language R. Probes were filtered by detec-
tion P-value, in which a P-value < 0.01 was considered
trustworthy. Background correction was carried by quan-
tile normalization and CpGs in SNPs were excluded. M
and beta values were calculated using minfi, and M val-
ues were subsequently used for downstream statistical anal-
ysis, using the limma package, to obtain P-value and ad-
justed P-value (Benjamini–Hochberg-calculated FDR) be-
tween sample groups by an eBayes-moderated paired t-test.
P-value of < 0.01 and FDR of < 0.05 was considered sta-
tistically significant.
Gene ontology, motif and pathway enrichment analyses
Gene ontology (GO) analysis of DNA methylation was car-
ried out using GREAT online tool (http://great.stanford.
edu/public/html) (21) by applying the basal plus extension
settings to annotate genomic regions. Annotated CpGs in
the EPIC array were used as background, and GO terms
with P-value < 0.01 and FC > 2 were considered signifi-
cantly enriched. GO analysis of gene expression was carried
out using the online tool DAVID (https://david.ncifcrf.gov)
and annotated genes in the Clariom S array were used as
background. The Functional Annotation tool was used and
GO terms with P-value < 0.01 was considered significantly
enriched.
Motif enrichment analyses were performed using
HOMER motif discovery software (22) and analyses were
carried out using the statistical programming language
Unix. Annotated CpGs in EPIC array and genes in Clar-
iom S array were used as background for methylation and
expression analyses respectively. For DNA methylation,
a window of ±250 bp around the interrogated CpGs was
applied, and for gene expression, a window of –2000 bp
upstream of the TSSs of interrogated genes was applied. A
P-value < 0.01 defines a motif as significantly enriched.
Pathway enrichment analyses of gene expression were
carried out using GSEA (Gene Set Enrichment Analy-
sis) software. Genes were ranked by expression log2FC of
Cambinol-treated versus untreated M-CSF MACs, and a
Normalized Enrichment Score (NES) was calculated for
each hallmark as described in the original article (23).
Analyses of DNase I hypersensitivity and ChIP-seq of histone
modifications
DNase I hypersensitivity and ChIP-seq data of hi-
stone modifications H3K27ac, H3K4me1, H3K4me3,
H3K27me3, H3K36me3 and H3K9/14ac of MO and
MACs were downloaded from the BLUEPRINT portal
(http://dcc.blueprint-epigenome.eu/). More than three inde-
pendent datasets were downloaded for each histone mark
and ChIP-seq peaks were consolidated, filtering the peaks
with a q-value < 0.01 and a fold change ≥2 and using the
MSPC program (24) with the parameters -w = 1E−4, -s =
1E−8, and -c = 3.
RESULTS
SIRT1/2 become rapidly upregulated during macrophage
differentiation and their inhibition upregulates many
inflammation-related genes
MOs isolated from PBMCs by CD14 positive selection were
differentiated in vitro into MACs by the addition of M-
CSF for 5 days (16). In the absence of further stimuli, these
MACs retain a plastic phenotype, in which the cells are sus-
ceptible to polarization to either an inflammatory (M1) or
anti-inflammatory (M2) phenotype through the addition of
LPS or IL-10/IL-4 respectively (25–27). We observed an in-
crease of the SIRT1 protein levels after 24 h following M-
CSF addition that continued during the 5 following days,
suggesting an essential role of this deacetylase in M-CSF
MAC differentiation (Figure 1A). SIRT1 upregulation was
concomitant with a decrease in its substrate H4K16Ac (Fig-
ure 1A). The upregulation of SIRT1 occurred in parallel
with SIRT2 (Figure 1B). The two sirtuins did not experience
Nucleic Acids Research, 2020, Vol. 48, No. 2 669
A







































































































































Negative regulation of immune system
Phagosome
p53 signaling pathway
Regulation of immune system process
Immune system process
Cancer
Negative regulation of gene expression
DNA replication
Systemic lupus erythematosus









































































< 0.05 & >= 0.01













































































































































































S0 1 3 5
*
Figure 1. Inhibition of SIRT1/2 with cambinol during MO-to-MAC differentiation results in an aberrant pro-inflammatory phenotype. (A) A represen-
tative western blotting analysis showing SIRT1 and acetylated lysine 16 of histone H4 (H4K16ac) protein expression of peripheral blood CD14+ MOs
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further changes in their protein levels following LPS stimu-
lation (Figure 1B). SIRT1 mRNA levels remained relatively
stable during this process (Figure 1B), indicating that the in-
crease at the protein level was due to post-transcriptional
mechanisms. Contrastingly, SIRT2 RNA became signifi-
cantly upregulated during MO-to-MAC differentiation in
parallel to its protein levels (Figure 1B). The rapid upregu-
lation of these sirtuins during MAC differentiation are con-
sistent with their described roles in MAC biology, as well as
suggesting a potential role during MAC differentiation.
Subsequently, we inhibited SIRT1/2 activity utilizing
cambinol, and inhibition efficiency was ascertained by
the increase in acetylated p65, a target of SIRT1/2 (4),
in cambinol-treated MACs (Supplementary Figure S1A).
Consequently, we observed that cambinol-treated MACs
underwent various phenotypic changes, including a de-
crease in the release of anti-inflammatory cytokine IL-10
both before and after LPS stimulation, and increased re-
lease of IL-1 after activation (Figure 1C). We also ob-
served that cambinol treatment resulted in the downregu-
lation of the macrophage scavenger receptor CD163 and
upregulation of inflammatory surface markers including
CD86, CD80 and CD83 (Figure 1D). Further gene expres-
sion analysis revealed that upon cambinol treatment, MACs
upregulated such proinflammatory genes as IL1B, IL1A
and TNF before and in some cases after LPS activation, and
downregulated CD163 expression after LPS treatment (Fig-
ure 1E). Analyses utilizing specific inhibitors against SIRT1
(EX527) and SIRT2 (AGK2) suggested a stronger effect
upon SIRT1 inhibition compared to SIRT2 inhibition (Sup-
plementary Figure S1B); however, both inhibitors, even in
combination, yielded weaker effects than cambinol.
To better characterize the impact of SIRT1/2 inhibi-
tion, we hybridized expression microarrays with MOs, M-
CSF MACs and cambinol-treated M-CSF MACs and ob-
served that cambinol treatment during MO-to-MAC differ-
entiation resulted in the significant (FDR < 0.05) upreg-
ulation and downregulation of 303 and 533 genes respec-
tively (Figure 1F). More specifically, many genes associated
with the inflammatory niche were transcriptionally upreg-
ulated when SIRT1/2 was inhibited (Supplementary Table
S2). Further gene ontology analyses revealed that upregu-
lated genes were enriched in categories including immune
response, myeloid activation, and Toll-like receptor and IL-
6 signalling. Regarding downregulated genes, we observed
enrichment in categories such as cell cycle, DNA replica-
tion, nucleosome organization, and E2F targets (Figure 1G,
Supplementary Figure S1C). TF motif enrichment analyses
revealed the participation of factors such as NF-kB, which
is a known target of SIRT1/2 and relevant to inflammation,
in the set of upregulated genes (Figure 1H).
Altogether, SIRT1/2 inhibition during macrophage dif-
ferentiation resulted in the acquisition of a more pro-
inflammatory signature, suggesting a role for these deacety-
lases in the silencing of inflammatory genes prior to MAC
polarization.
SIRT1/2 activity is dispensable for active demethylation
but determines de novo gains of DNA methylation during
macrophage differentiation
MO to MAC differentiation is accompanied by large-scale
DNA methylation changes, both gains and losses of methy-
lation, which are critical to the acquisition of the final phe-
notype of MACs (16,28,29). Given that SIRT1/2 partici-
pates in macrophage differentiation and their inhibition re-
sults in broad changes in gene expression, we investigated
their potential interplay with DNA methylation changes.
Utilizing high density bead arrays, we observed that 7475
CpGs became demethylated (FDR < 0.05; hypomethy-
lated cluster) upon MAC differentiation from MO, and
this demethylation was not affected when SIRT1/2 were
inhibited by cambinol, suggesting that they do not par-
ticipate in active demethylation (Figure 2A and B, top).
The hypomethylated cluster included CpGs of genes asso-
ciated with innate responses, such as TM7SF4, ACP5 and
ADAM12, and displayed enrichment in motifs of the bZIP
family of TFs, in concordance to a previous study (Supple-
mentary Figure S2B-D) (16). Conversely, 2652 CpGs gained
de novo methylation (FDR < 0.05; hypermethylated clus-
ter) during MAC differentiation, and surprisingly, inhibi-
tion of SIRT1/2 in turn inhibited almost all CpG methy-
lation gains, which suggested that SIRT1/2 activity is re-
quired for MAC-associated DNA hypermethylation (Fig-
ure 2A and B, bottom). Analyzing variance between sam-
ples using principal component analysis (PCA), we showed
that for demethylated CpGs, MACs and cambinol-treated
MACs displayed overlapping PC dimensions. In contrast,
for hypermethylated CpGs, the three cell populations sep-
arated along the axis of PC1, in which cambinol-treated
MACs showed less PC1 variance with MOs than MACs
(Figure 2C). Further analyses of CpG positioning revealed
that both hyper- and hypomethylated CpGs were enriched
in open seas with a slight enrichment in 5′-UTR compared
to background (Supplementary Figure S2A). GO analysis
revealed that most of the genes associated with hyperme-
thylated CpGs were enriched in functional categories re-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
stimulated with 25 ng/mL of M-CSF for 0, 1, 3 and 5 days. Relative band intensities of SIRT1 and H4K16ac were normalised against -Actin and H4 re-
spectively (right panel) from two independent experiments. (B) Western blot analysis of protein expression of SIRT1 and SIRT2 in MO exposed to M-CSF
for 0, 1, 3 and 5 days and activated by the addition of LPS for 18 hrs. RNA expressions of SIRT1 and SIRT2 were normalised against RPL38. (C) Secreted
levels of IL-10 and IL-1 were analysed by ELISA in MACs differentiated in the presence of DMSO or treated with 50 nM of cambinol. (D) FACS analysis
of surface markers CD163 (FITC), CD86 (APC), CD80 (PE) and CD83 (APC) in MOs and M-CSF MACs before and after treatment with LPS for 18
hrs in the presence and absence of cambinol (50 nM). (E) Gene expression analysis of IL1B, IL1A,TNF and CD163 in MOs, cambinol- or DMSO-treated
M-CSF MACs differentiated for 5 days and MACs treated with LPS for an additional 18 hrs. (A-E) Statistical significance of at least three independent
experiments was calculated by paired student t-test (* p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001). (F) Heatmap representation of z-scores
obtained from log2 expression of genes that undergo significant changes (FDR < 0.05) in cambinol-treated (M-CSF + Camb) compared to DMSO-treated
(M-CSF) MACs, in which 533 and 303 genes become downregulated (log2FC < 0 and FDR < 0.05) and upregulated (log2FC > 0 and FDR < 0.05) re-
spectively. (G) GO analyses of cambinol-downregulated (left) and -upregulated (right panel) genes using the DAVID tool (https://david.ncifcrf.gov). (H)
Bubble plot representation of HOMER TF motif enrichment analysis. A window of -2000 bp upstream of TSS was used for all genes analysed.
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Figure 2. Inhibition of SIRT1/2 inhibition with cambinol affects DNA hypermethylation during MO-to-MAC differentiation. (A) Heatmap representa-
tion of significant (FDR < 0.05) DNA methylation changes during MO-to-MAC differentiation comparing DMSO-treated MACs (M-CSF) with MOs.
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lated to macrophage biology including inflammatory re-
sponse, cytokine receptor activity and leukocyte migration,
and these genes include ADORA2A, RUNX3, IL2RA, TN
FAIP3, JAK3, SLC1A2, ADAMDEC1 and CD83 (Figure
2D and E). These results suggested that gains of methyla-
tion at genes associated with these biological processes were
altered when SIRT1/2 were inhibited. Inspection of the pro-
tein levels of DNMTs revealed a significant downregulation
of DNMT3A protein in cambinol-treated MACs, with both
DNMT1 and DNMT3B displaying similar trends with-
out reaching statistical significance (Supplementary Figure
S2E).
Sequences associated with hypermethylated CpGs were
enriched in a distinct set of TFs, namely members of the
ETS family (Figure 2F). Previously, PU.1 and other mem-
bers of the ETS TF family was linked to hypermethylated
regions in terminal myeloid differentiation model, in which
PU.1 was observed to recruit DNMT3B to mediate de novo
DNA methylation (30). Therefore, given these results, it is
conceivable that SIRT1/2 activity is required for ETS TF-
mediated recruitment of DNMTs to hypermethylated CpG
sites.
SIRT1 determines the epigenetic landscape not only
through its ability to directly deacetylate H1, H3 and H4
(31–33), but also through the post-translational regulation
of other histone-modifying enzymes (34). Given the role
of SIRT1 in histone modifications and its effect on DNA
methylation, we then analyzed the enrichment of various
histone marks in both MOs and MACs, obtained from
publically available Blueprint ChIP-seq data (http://dcc.
blueprint-epigenome.eu; refer to Materials and Methods
for the consolidation of data), in the hypermethylated CpG
cluster. We observed that there was a significant enrich-
ment in DNase I hypersensitivity in MOs which decreased
in MACs, coupled with significant enrichment of H3K4me1
in both cell types (Figure 2G). These observations were in
accordance to what has been previously described in regards
to the relationship between DNA methylation and chro-
matin states, in which gains of DNA methylation in regions
of enhancers correspond to heterochromatin (35,36).
SIRT1/2 activity is required to prevent premature expression
of pro-inflammatory genes upon LPS stimulation through
premeditated DNA hypermethylation
The relationship between DNA methylation and gene ex-
pression has been nothing short of controversial. It is
widely accepted that DNA methylation inhibits gene ex-
pression, however mounting evidence suggest a more com-
plicated reciprocal relationship (reviewed by Jones et al.
(37)). To evaluate the relationship between gene expression
and DNA methylation in relation to SIRT1/2 inhibition,
we first mapped the hypermethylated CpGs to the near-
est gene, yielding 1612 unique genes (Figure 3A). Surpris-
ingly, only 63 genes (3.9%) displayed upregulation and 61
genes (3.8%) displayed downregulation mediated by cam-
binol treatment, whereas 92.3% of genes showed no sig-
nificant gene expression changes despite the inhibition of
DNA hypermethylation (Figure 3B, right panel). In con-
trast, majority of genes from the hypermethylated CpG
cluster did display a significant change in expression dur-
ing the MO-to-MAC differentiation step; however, both
upregulation and downregulation were observed (Figure
3A, left panel), which emphasized the complex relation-
ship between DNA methylation and gene expression. Since
the pro-inflammatory phenotype observed in cambinol-
exposed MACs appeared more pronounced following LPS-
mediated activation (Figure 1C–E), it is therefore of interest
to interrogate the expression of genes associated to hyper-
methylated CpGs following LPS stimulation. Interestingly,
upon LPS-stimulation, genes such as ADORA2A, RUNX3,
IL2RA, TNFAIP3, JAK3, SLC1A2, ADAMDEC1, TLR2,
INHBA, JUN, TNFAIP8, RUNX1, previously described to
be upregulated upon LPS stimulation (38), displayed fur-
ther upregulation in cells exposed to cambinol (Figure 3C),
indicating that SIRT1/2 determined, at least in part, their
repression, and DNA methylation might participate in tight
control of their repressive status prior to polarization to a
pro-inflammatory phenotype.
SIRT1/2 play concurrent roles in de novo gains of DNA
methylation and histone modifications in macrophage differ-
entiation and activation
Our results showed that the activities of SIRT1/2 deter-
mined de novo DNA methylation during MO-to-MAC dif-
ferentiation. It is likely that acquisition of DNA methy-
lation is accompanied by additional histone modifica-
tions. Hence, we analyzed the enrichment of histone
marks H3K9/14ac, H3K4me3, H3K4me1, H3K36me3,
H3K27me3 and H3K27ac, as well as DNase I hypersen-
sitive sites, all obtained from the Blueprint database, in
MOs and MACs within a window of 4000 bp centring
around hyper- and hypomethylated CpGs (Figure 4A).
We observed that for CpGs whose hypermethylation dur-
ing MO-to-MAC differentiation was blocked in cambinol-
treated MACs, they appeared to undergo a dramatic de-
crease in DNase I hypersensitivity and reduced H3K4me3
and H3K27ac histone marks, which were in accordance to
a more closed chromatin profile (39,40). We also observed
a slightly higher enrichment of H3K4me1 in MACs with
respect to MOs, which marks primed enhancers (41). Con-
versely, we observed that for CpGs whose MO-to-MAC
demethylation was not affected by SIRT1/2 inhibition, they
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(B) Violin plots depicting the distribution and probability density of z-scores of hypo- (upper) and hypermethylated (lower panel) CpGs. (C) Principal
component analysis (PCA) of hypo- and hypermethylated CpGs of the three cell populations (Mo, M-CSF and M-CSF + Camb). (D) GO analysis of
hypermethylated CpGs, in which CpGs were mapped to genes using GREAT online tool (http://great.stanford.edu/public/html) by applying the basal
plus extension settings, using EPIC array as background. (E) Representation of the beta values of selected hypermethylated CpGs that map to relevant
genes. (F) HOMER TF motif enrichment analysis of hypermethylated CpGs were carried out using a window of ±250 bp centring around the CpGs.
CpGs annotated in the EPIC 850K array were used as background. (G) Histone marks enrichment analysis of hypermethylated CpGs were carried out
by crossing DNase-seq and ChIP-seq data of H3K9me3, H3K9/14ac, H3K4me3, H3K4me1, H3K36me3, H3K27me3 and H3K27ac of MOs and MACs
downloaded from the Blueprint database (refer to Materials and Methods for data processing).
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Figure 3. Treatment with cambinol upregulates pro-inflammatory genes associated to hypermethylated CpGs following MAC activation with LPS. (A)
Color-coded heatmap representation of gene expression of hypermethylated CpGs of the three cell populations (MO, M-CSF and M-CSF + Camb). 2652
hypermethylated CpGs were mapped to 1612 unique genes utilizing GREAT online tool with the setting of mapping to the nearest gene. (B) Scatter plots
representing log2FC of gene expression (y-axis) and difference in beta (beta; x-axis) of M-CSF in respect to MOs (left panel) and M-CSF + Camb in
respect to M-CSF MACs (right panel). Genes that show significant (FDR < 0.05) upregulation or downregulation are depicted in red and blue respectively.
(C) Gene expression analyses of ADORA2A, RUNX3, IL2RA, TNFAIP3, JAK3, SLC1A2, ADAMDEC1, TLR2, INHBA, JUN, TNFAIP8, RUNX1 in
MOs, MACs and LPS-activated MACs in the presence and absence of 50 M cambinol. Bar graphs represent mean and standard deviation of relative
expression of each gene of four independent experiments normalized against RPL38. Statistical significance was calculated using paired Student’s t-tests
(*P-value < 0.05, **P-value < 0.01 and ***P-value < 0.001).
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Figure 4. MO-to-MAC DNA methylation gains occur concomitantly with a loss of DNase I hypersensitivity and activating histone marks, and SIRT1/2
inhibition upregulates activating histone marks. (A) DNase-seq and ChIP-seq data of H3K27ac, H3K4me1 and H3K4me3 of MOs and MACs were
downloaded from the Blueprint database (refer to Materials and Methods for details). Odds ratios were calculated for bins of 10 bp up to ±2500 bp
centering around hypo- (left panel) and hypermethylated (right panel) CpGs in which CpGs annotated in the EPIC 850K array were used as background.
(B) Schematic representation of DNase I hypersensitivity, H3K27ac, H3K4me3 and H3K4me1 marks near hypermethylated CpGs in ADORA2A, RUNX3,
IL2RA and JAK3. MOs are represented in red and MACs are represented in blue. (C) Chromatin immunoprecipitation (ChIP) of H4K16ac (yellow),
H3K4me1 (green), H3K4me3 (light blue) and H3K27ac(dark blue) MOs, MACs and LPS-activated MACs in the presence and absence of 50 M cambinol.
ChIP amplicon positions in relation to hypermethylated CpGs and genes ADORA2A, RUNX3, IL2RA and JAK3 are depicted in (B). Three independent
experiments were performed and statistical significance was calculated using paired Student’s t-tests (*P-value < 0.05, **P-value < 0.01 and ***P-value
< 0.001).
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underwent an increase in DNase I accessibility, concur-
rently with higher enrichment in H3K4me3, H3K27ac and
H3K4me1 in MACs compared to MOs. No significant dif-
ferences were observed for H3K27me3, H3K36me3 and
H3K9/14ac, which was due, in part, to lack of data to
generate sufficient and reliable reads (Supplementary Fig-
ure S3A). Altogether, these results suggest that gains and
losses of DNA methylation during MO-to-MAC differen-
tiation occur concomitantly with changing histone marks
and chromatin accessibility, in which SIRT1/2 inhibition
specifically inhibited MO-to-MAC gains of methylation.
Hence, it is not unbefitting to envision that SIRT1/2 may
have additional implications in the modification of the chro-
matin landscape.
To further understand the hierarchy between the estab-
lishment of histone marks by SIRT1/2 and DNA methyla-
tion and their effect on gene expression, we performed ChIP
analyses of H3K4me1, H3K4me3, H3K27ac and H4K16ac
in MOs, MACs and cambinol-treated MACs, both before
and after LPS activation, in LPS-responsive genes with
hypermethylated CpGs. First, we observed a general loss
of active histone marks in the MO-to-MAC differentia-
tion process, which was in accordance with what was ob-
served in the Blueprint data (Figure 4B). Second, we ob-
served that SIRT1/2 inhibition by cambinol not only re-
sulted in enrichment of H3K16ac but also in H3K4me3
and H3K27Ac at several proinflammatory loci, both be-
fore and following LPS challenge (Figure 4C), and these
included ADORA2A, RUNX3 and JAK3. A similar trend
was observed in IL2RA, however it did not reach statisti-
cal significance. These results indicated that SIRT1/2 are
required to maintain a closed chromatin structure at proin-
flammatory loci through DNA hypermethylation and the
inhibition of activating histone marks. Interestingly, cambi-
nol treatment already results in histone modifications prior
to MAC activation, however, aberrant upregulation of these
genes was mostly observed following LPS stimulation (Fig-
ure 3C). These results suggest that alteration of the histone
modification status was not sufficient to induce aberrant ex-
pression, hence an additional stimulus was required. In all,
our results proved that SIRT1/2 are essential in the estab-
lishment of chromatin structure at pro-inflammatory genes,
as their functions are not only critical to achieve correct
gains of DNA methylation during MO-to-MAC differenti-
ation but is also required for both the loss of active histone
marks and their maintenance during differentiation and ac-
tivation respectively.
Inhibition of DNA methylation alone is sufficient to aber-
rantly upregulate proinflammatory genes in LPS-activated
MACs
The strict association between the cambinol-mediated aber-
rant upregulation of genes following encounter with LPS
stimulus and their previous inhibition of DNA methylation
led us to speculate on the direct relevance of DNA methyla-
tion in the transcriptional status of pro-inflammatory genes
following activation. To test such hypothesis, we differen-
tiated MACs in the presence of a bona fide DNMT in-
hibitor, 5-aza-2′-deoxycytidine (DAC) (42). Firstly, utiliz-
ing pyrosequencing, we confirmed that MACs differenti-
ated in the presence of cambinol and DAC displayed an ef-
fective inhibition in gains of DNA methylation both before
and after LPS exposure (Figure 5A). Secondly, in parallel
to what was observed in cambinol-treated cells, we also ob-
served a significant upregulation of such LPS-induced genes
as ADORA2A, RUNX3, TNFAIP3 and SLC1A2 in MACs
treated with DAC following LPS stimulation (Figure 5B).
Other genes such as IL2RA, JAK3 and ADAMDEC1 dis-
played a trend in their upregulation without reaching sta-
tistical significance (Figure 5B). Interestingly, we did not
observe an upregulation in these genes prior to LPS stim-
ulation (Supplementary Figure S4A), suggesting that, sim-
ilar to cambinol, LPS stimulus was required for their aber-
rant expression. Finally, DAC-treated MACs secreted sig-
nificantly less IL-10 following LPS stimulus (Figure 5C),
however no changes in IL-1 secretion were observed. Al-
together, these results suggested that the inhibition of DNA
methylation alone by DAC is sufficient to induce tran-
scriptional activation of proinflammatory genes in the pres-
ence of functional sirtuins, and, to some extent, mediated a
change in the final functional phenotype of MACs.
Both SIRT1 and SIRT2 interact with DNMT3B and are
recruited to genes that become hypermethylated during
macrophage differentiation
To better understand the relationship between SIRT1/2 and
the DNA methylation machinery in MACs in relation to
the control of proinflammatory genes, we then performed
co-immunoprecipitation experiments to assess the potential
interaction between SIRT1/2 with DNMTs. Immunopre-
cipitation, performed using M-CSF MACs differentiated
from MOs for 5 days, showed that both SIRT1 and SIRT2
co-immunoprecipitated with DNMT3B, but not DNMT1
and DNMT3A (Figure 6A). Interestingly, DNMT3B and
DNMT3A also seemed to interact with each other (Fig-
ure 6A). Such interaction has been previously described in
other cell types (43,44). Furthermore, the interaction be-
tween DNMT3B and SIRT1/2 was not affected by cambi-
nol treatment (Figure 6B). Subsequently, we tested the re-
cruitment of sirtuins to inflammatory loci that become hy-
permethylated during MAC differentiation in the presence
of cambinol in unstimulated and LPS-activated MACs. We
first observed an increase in SIRT1 and SIRT2 binding
to SLC1A2, TNFAIP3 and ADORA2A loci upon MO-to-
MAC differentiation, in which the complex appeared to
dissociate following LPS stimulation. Second, we observed
that their binding was abrogated upon inhibition with cam-
binol both before and after LPS stimulation (Figure 6C).
Finally, and remarkably, we also observed binding of PU.1
to these genes, in which the pattern of binding of PU.1 was
very similar to SIRT1 and 2 (Figure 6C). We were unable to
detect binding of DNMT3A/B to these sequences, however,
we could not discard that this was a technical limitation due
to the quality of the DNMT antibodies.
Utilizing specific pharmacological inhibitors targeting
SIRT1 and SIRT2, we observed that inhibition of SIRT1
may have a stronger effect on gene expression than SIRT2
(Supplementary Figure S1C). Thus in order to assess the
specific contribution of sirtuins to DNA hypermethylation
and expression of inflammatory genes, we downregulated
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Figure 5. Inhibition of DNA methylation alone is sufficient to upregulate gene expression following LPS exposure. (A) Pyrosequencing of hypermethylated
CpGs mapped to TNFAIP3, RUNX3, IL2RA, ADORA2A, and JAK3 in MOs (gray), MACs and LPS-activated MACs in the presence of DMSO (green),
50 M cambinol (orange) and 10 M DAC (light orange) or remained untreated (light green). Untreated MACs were controls for DAC and DMSO-
treated MACs were controls for cambinol. Three independent experiments were performed. (B) Gene expression analysis of TNFAIP3, RUNX3, IL2RA,
ADORA2A, JAK3, SLC1A2, and ADAMDEC1 of MACs differentiated in the presence of 50 M of cambinol or 10 M of DAC and subsequently activated
with 10 ng/mL of LPS for 18 hrs. Gene expression were normalized against housekeeping gene RPL38 and represented as fold changes against control
(MACs treated with corresponding volumes of DMSO for cambinol or untreated for DAC). Four independent experiments were performed. (C) ELISA
analyses of IL-1 and IL-10 secretion in M-CSF MACs differentiated for 5 days and activated with 10 ng/mL LPS for an additional 18 hrs in the presence
of 50 M of cambinol or 10 M of DAC. DMSO-treated and untreated MACs were used as controls. Four independent experiments were performed. All
statistical analyses were performed using paired Student’s t-tests (*P-value < 0.05, **P-value < 0.01 and ***P-value < 0.001).
SIRT1 and SIRT2 using siRNAs. We were able to downreg-
ulate SIRT1 and SIRT2 with distinct efficiency, achieving
65% and 95% reduction in protein expression respectively
(Figure 6D). We observed that upon SIRT1 knockdown,
there was significant inhibition in the acquisition of MO-to-
MAC DNA methylation for CpGs annotated to TNFAIP3,
JAK3, RUNX3 and ADORA2A. Conversely, SIRT2 knock-
down did not appear to have an effect on DNA methyla-
tion, except in the case of JAK3 (Figure 6E). Knockdown
of either sirtuins did not have an effect on hypomethy-
lated CpGs (Supplementary Figure S4A). Moreover, the
inhibition of DNA methylation gain observed in ΔSIRT1
MACs correlated with an aberrant upregulation of the same
genes following LPS stimulation, albeit some did not reach
statistical significance (Figure 6F). Similar to what was
observed with pharmacological inhibitors, SIRT1 down-
regulation appeared to have stronger impact compared to
SIRT2. These observations suggest that SIRT1 is the main
player mediating the acquisition of DNA methylation dur-
ing MAC differentiation.
DISCUSSION
In this study, we report a novel role for SIRT1/2 in
macrophage differentiation, in which these deacetylases act
as a key element in establishing the hierarchy of epige-
netic modifications involving acquisition of de novo DNA
methylation through direct DNMT3B interaction, linked
to H3K4me3 demethylation and H3K27ac deacetylation,
to prevent premature activation of pro-inflammatory genes
during MAC differentiation and prior to encounter with
bacterial antigens.
Our initial observation showed that both SIRT1 and
SIRT2 undergo a drastic upregulation concomitant with
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Figure 6. SIRT1 and 2 interact with DNMTs to drive DNA hypermethylation at inflammatory loci. (A) Co-immunoprecipitation assays were per-
formed in MOs differentiated to MACs in the presence of M-CSF for 5 days. Protein extracts were immunoprecipitated utilising anti-DNMT1, -
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MAC differentiation, and that the effects of SIRT1/2 in-
hibition during this process impact the expression levels of
many genes related to the immune properties of these cells,
with a particular effect on proinflammatory genes mediat-
ing their aberrant upregulation. These observations support
a major role of SIRT1/2 in maintaining a repressed status
for these genes, most likely through the direction interaction
with DNMTs, which is in concordance to what has been
observed in other studies. Notably, SIRT1 has been previ-
ously described by Park et al. to exert anti-inflammatory
effects in RA macrophages through the inhibition of NF-
B signalling, and SIRT1 Tg-mice displayed reduced M1
polarization (10). Individual siRNA knockdown of SIRT1
and SIRT2 showed that the former mediated loss of DNA
methylation and upregulated proinflammatory gene expres-
sion while the latter had weaker significant effects. It is
therefore likely that SIRT1 is the major contributor to the
phenotype of M-CSF macrophages while SIRT2 may offer
little or no contribution.
Interestingly, the analysis of DNA methylation changes
in relation to inhibition and downregulation of SIRT1/2
shows that only gains of DNA methylation are affected,
in contrast to DNA demethylation, which is identical to
those without SIRT1/2 inhibition. Remarkably, the group
of genes that gain methylation during macrophage differ-
entiation, almost all of which are affected by SIRT1/2 in-
hibition, associate with additional epigenetic features in-
cluding a decrease in H3K27ac and H3K4me3 and an
increase in H3K4me1. These observations indicate that
these three histone marks are linked to the observed gains
of DNA methylation. Different studies have established
links between DNA methylation and histone modifications.
First, the presence of DNA methylation has originally been
described to prevent methylation of H3K4 (45). Second,
treatment with DNMT inhibitors were shown to increase
H3K4me2 and H3K4me3 occupancy at target promoters
and gene bodies, as well as resulting in a dramatic increase
in enhancer activity (46). Furthermore, structural and bio-
chemical studies have shown a direct interaction between
the catalytic domain of de novo DNA methyltransferases
with unmethylated H3K4 histone peptide leading to the cat-
alytic activation of DNMT3A (47,48). This interaction was
in turn inhibited by H3K4 methylation and histone acety-
lation (49). Taken together, evidence suggests an inverse re-
lationship between DNA methylation and H3K4 methyla-
tion. Third, histone remodelers of H3K4 have been linked
to DNMT3 recruitment and activity, in which MLL4 en-
hances DNMT3A-catalyzed DNA methylation at super-
enhancers (50), and contradictorily LSD1 has been de-
scribed to function in a complex with DNMT3 to medi-
ate both H3K4 demethylation and DNA methylation at
pluripotentency enhancers (51). Finally, DNA methylation
has been described to inversely correlate with acetylated
H3K27 deposition, a classical marker for enhancers (39),
however, recent studies also identified bivalent regions, in
which H3K27ac co-exists with DNA methylation, although
this accounts for a minority of CpGs (38%) (52). Our
findings reinforce the connection between DNA methyla-
tion and H3 modifications, in which DNA methylation lev-
els inversely correlate with H3K4me3 and H3K27ac (Fig-
ure 4), as such that the inhibition of SIRT1/2 mediates
higher enrichment of these two histone marks concurrently
with a decrease in DNA methylation prior to encounter
with bacterial antigen. Furthermore, CpGs that become
demethylated upon SIRT1/2 inhibition also gain H4K16ac,
which is coherent with the role of SIRT1/2 in its deacetyla-
tion. Altogether, these results indicate that the activities of
SIRT1/2 are essential in the maintenance of a silent chro-
matin, defined by DNA hypermethylation and low levels of
H3K4me3, H3K27ac and H4K16ac, and their inhibition re-
sults in chromatin aperture.
The dynamics between SIRT1/2 and DNMTs has been
partly elucidated by our results, in which we have observed
a direct interaction between SIRT1/2 and DNMT3B, which
in turn interacts with DNMT3A. Other studies had pre-
viously linked SIRT1 activity with DNMTs. For instance,
O’Hagan et al. showed that SIRT1 recruitment to induced
double-strand breaks was dependent on DNMT1, and that
DNMT1, DNMT3B and SIRT1 form part of a large multi-
protein complex following oxidative DNA damage (43).
We observe that the binding of SIRT/DNMT3B complex
to chromatin appears to be dependent on SIRT1/2 ac-
tivity, and it is possible that other transcription factors,
such as PU.1, may target the complex to repress pro-
inflammatory genes in M0 MACs. Furthermore, the inter-
action of SIRT1/2 with DNMTs may also participate in the
direct deacetylation of these enzymes to modify their ac-
tivities in a similar way that has been observed for SIRT1
and DNMT3L (53). Additionally, SIRT1 has also been in-
directly linked to DNA methylation through its activities
of modifying histones. One such example was described by
Aguilar-Arnal et al. where SIRT1 was observed to directly
deacetylate MLL1 and modulate H3K4 tri-methylation
along the circadian cycle (54). Since H3K4 methylation play
concerted roles with DNA methylation, it is therefore plau-
sible that SIRT1 can modulate DNA methylation through
histone modifications.
The hierarchy of DNA methylation, histone modifica-
tions and gene expression has been proven to be extremely
complex, in which contradictory literature has described
DNA methylation as both a cause and a consequence of
changes in gene expression. While it is generally accepted
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
DNMT3A, -DNMT3B, -SIRT1 and –SIRT2 antibodies, in which IgG was used as a negative control and total protein extract was used as input. (B)
Co-immunoprecipitation of MACs differentiated in the presence of DMSO or 50 M cambinol for 5 days. (C) Chromatin immunoprecipitation of two
independent experiments of SIRT1 (pink), SIRT2 (red) and PU.1 (blue) was performed in isolated monocytes and MACs differentiated in the presence of
M-CSF for 5 days in the presence and absence of cambinol, before and after LPS stimulation for 18 hrs. (D) MOs were transfected with 100nM of corre-
sponding siRNA and differentiated to MACs in the presence of M-CSF for 5 days, as described in Materials and Methods. Annotated numbers indicate
relative band intensities compared to non-targeting control (NT). (E) Pyrosequencing of hypermethylated CpGs in MOs and MACs transfected with NT,
siSIRT1 and siSIRT2 prior to LPS activation. (F) Gene expression of SCL1A2, TNFAIP3, JAK3, RUNX3 and ADORA2A in MOs and LPS-activated
MACs transfected with NT, siSIRT1 and siSIRT2, as normalised against RPL38. (D-F) Statistical significance of at least three independent experiments
was calculated using paired student t-tests (* p-value < 0.05, ** p-value < 0.01 and *** p-value < 0.001).
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that DNA methylation results in gene repression, however,
recent studies have provided conflicting evidence in their
relationship. One study involving 62 unrelated individuals
concluded that DNA methylation contributes to only 8%
of inter-individual gene expression variation (55). Similarly,
another study shows that the presence of DNA methyla-
tion is insufficient to transcriptionally repress promoters
(56). This conclusion was, however, recently refuted by Ko-
rthauer et al., as the authors show that, by utilizing differ-
ent statistical strategies that include statistical inference of
differentially methylated regions and additional normaliza-
tion techniques, promoter DNA methylation indeed corre-
late negatively with gene expression (57). Nevertheless, the
role of DNA methylation during a cell activation event, such
as encounter with bacterial antigens, is still unknown. In a
study conducted in our laboratory, Vento-Tormo et al. show
that a previous demethylation step, together with histone
modifications, is required for correct upregulation of in-
flammatory genes during dendritic cell activation (28). Con-
trastingly, a more recent article shows that upregulation of
proinflammatory genes precedes DNA demethylation fol-
lowing dendritic cell activation, however, this behavior only
accounts for less than 10% of all differentially expressed
genes and differentially methylated CpGs (58). In this study,
we provide a direct link between DNA methylation, histone
modifications and gene expression. We show that SIRT1/2-
dependent establishment of correct chromatin state prior to
LPS challenge is essential for proper and controlled expres-
sion of proinflammatory genes following macrophage acti-
vation. In fact, we demonstrate that the majority of DNA
methylation gains and histone modifications are established
in the MO-to-MAC differentiation step, similar to what
were observed by Vento-Tormo and colleagues, and their
disruption by cambinol results in aberrant post-LPS upreg-
ulation of proinflammatory genes. Furthermore, we demon-
strate the essentiality of DNA methylation in gene expres-
sion by specifically inhibiting MO-to-MAC DNA hyperme-
thylation utilizing DAC, and we show that although DAC
inhibits methylation prior to LPS challenge, aberrant upreg-
ulation of gene expression is not observed until after MAC
activation.
In conclusion, our work directly identifies SIRT1/2,
through direct interaction with DNMTs, as essential fac-
tors in the establishment of gains of methylation, as well as
additional epigenetic modifications that prevent premature
expression of proinflammatory genes during differentiation
to MACs and prior to their encounter to bacterial antigens.
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58. Pacis,A., Mailhot-Léonard,F., Tailleux,L., Randolph,H.E.,
Yotova,V., Dumaine,A., Grenier,J.-C. and Barreiro,L.B. (2019) Gene
activation precedes DNA demethylation in response to infection in
human dendritic cells. Proc. Natl. Acad. Sci. U.S.A., 116, 6938–6943.
